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A bstract
Background:Treg based immunotherapy is of great interest to facilitate tolerance in autoimmunity and transplantation. For 
clinical trials, it is essential to have a clinical grade Treg isolation protocol in accordance with Good Manufacturing Practice 
(GMP) guidelines. To obtain sufficient Treg for immunotherapy, subsequent ex vivo expansion might be needed.
Methodology/Principal Findings: Treg were isolated from leukapheresis products by CliniMACS based GMP isolation 
strategies, using anti-CD25, anti-CD8 and anti-CD19 coated microbeads. CliniMACS isolation procedures led to 40-60% pure 
CD4posCD25highFoxP3pos Treg populations that were anergic and had moderate suppressive activity. Such CliniMACS 
isolated Treg populations could be expanded with maintenance of suppressive function. Alloantigen stimulated expansion 
caused an enrichment of alloantigen-specific Treg. Depletion of unwanted CD19pos cells during CliniMACS Treg isolation 
proved necessary to prevent B-cell outgrowth during expansion. CD4posCD127pos conventional T cells were the major 
contaminating cell type in CliniMACS isolated Treg populations. Depletion of CD127pos cells improved the purity of 
CD4posCD25highFoxP3pos Treg in CliniMACS isolated cell populations to approximately 90%. Expanded CD127neg CliniMACS 
isolated Treg populations showed very potent suppressive capacity and high FoxP3 expression. Furthermore, our data show 
that cryopreservation of CliniMACS isolated Treg is feasible, but that activation after thawing is necessary to restore 
suppressive potential.
Conclusions/Significance:The feasibility of Treg based therapy is widely accepted, provided that tailor-made clinical grade 
procedures for isolation and ex vivo cell handling are available. We here provide further support for this approach by 
showing that a high Treg purity can be reached, and that isolated cells can be cryopreserved and expanded successfully.
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In tro d u c tio n
Regulatory T  cells (Treg) play a critical role in various 
immunological processes, particularly in maintaining homeostasis 
and self-tolerance. Im munotherapy based on Treg infusion is 
therefore a potential treatm ent for many immune disorders. This 
approach has been proven successful in animal models of stem cell 
transplantation [1—7], solid organ transplantation [8,9] and auto­
immunity [6,10-13]. Therapeutic application in humans requires 
large numbers of Treg, that have to be isolated and, if necessary, 
expanded using clinical grade (Good M anufacturing Practice, 
GMP) protocols. The CliniMACS system provides a relatively 
versatile method for GM P cell isolation and is able to manage 
large quantities of cells, for example from leukapheresis material.
O ther authors have recently shown the feasibility of CliniMACS 
for CD4posCD25high Treg enrichment, but failed to achieve Treg
purity of more than 40-60%  [14,15]. For stem cell transplantation 
recipients, a suboptimal Treg purity is unlikely to be harmful. 
Currently, many stem cell transplantation recipients are treated 
with donor lymphocyte infusions to enhance graft-versus-leuke- 
m ia/tum or responses. The main adverse effect of this treatm ent is 
graft-versus-host-disease (GVHD). The aim of Treg immunother­
apy in this patient group is to reduce these graft-versus-host 
responses. Co-infusion of both non-regulatory T  cells to ensure 
graft-versus-leukemia/tumor responses and Treg to prevent 
excessive GVHD is therefore a logical approach in this setting. 
However, in other patient groups, such as solid organ graft 
recipients and patients with auto-immune diseases, high purity of 
Treg for immunotherapy is crucial. Infusion of non-regulatory 
cells into patients that already suffer from unwanted immunolog­
ical activity should be prevented, as these cells can potentially 
intensify the disease process. The main aggressive cell types in
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immune responses are cytotoxic C D 8pos T  cells and CD4pos 
conventional T  cells, and contamination of CliniMACS isolated 
Treg populations with these cells should be avoided for 
immunotherapy in patients other than stem cell recipients. 
Likewise, contamination of the isolate with B cells could lead to 
the infusion of activated B cells with potential adverse immuno­
logical consequences.
Although CliniMACS based Treg isolation from leukapheresis 
products will yield large numbers of Treg, ex vivo expansion of 
these cells prior to infusion might still be necessary to obtain 
sufficient numbers of Treg for effective immunotherapy. Treg can 
be expanded efficiently using polyclonal stimulation [16-19]. 
However, antigen-specific Treg have been shown to be far more 
efficient than polyclonal Treg in animal models [3,5-7,12,13]. In 
allogeneic transplantation, the target antigens are known (mainly 
foreign HLA) and hum an alloantigen-specific Treg can be 
obtained by expansion using stimulation with alloantigen [20,21].
For practical reasons, it would be convenient or even necessary 
to perform the leukapheresis procedure weeks/months before the 
transplantation or treatm ent and store the Treg until they are 
needed. Currently, information on cryopreservation of Treg is 
lacking.
In the current study, we confirm that GM P Treg isolation using 
standard CliniMACS procedures results in moderately pure Treg 
populations. Here, we show that purity of CliniMACS isolated 
Treg can be improved by depletion of CD127pos cells. In addition, 
we show that CliniMACS isolated Treg can be expanded with 
maintenance of suppressive function using polyclonal or alloanti­
gen stimuli in the presence of IL-2. Depletion of CD19pos B cells 
during CliniMACS Treg isolation appears to be a prerequisite to 
prevent B cell outgrowth during expansion. Furthermore, we show 
that cryopreservation of Treg is feasible, but that the cells require 
activation to restore suppressive potential.
Results
Isolation of Treg using CliniMACS yields 40-60%  pure 
CD4posCD25high Treg populations with suppressive 
activity
Treg immunotherapy will demand very high numbers of highly 
pure Treg populations isolated in a GM P manner. To obtain large 
numbers of Treg with optimal purity, we performed 
CD4posCD25high T  cell isolation from healthy donor leukapheresis 
products using the GM P CliniMACS system. The most straight­
forward strategy to enrich for Treg would be a one step positive 
selection of CD25pos cells out of leukapheresis products. However, 
this strategy would unintentionally result in contaminating 
(activated) cytotoxic C D 8pos T  cells in the isolated Treg 
populations. Therefore, our initial CliniMACS isolation strategy 
consisted of two steps: first a C D 8 depletion step to exclude 
C D 8pos effector T  cells from the isolated cell populations, followed 
by a CD25 enrichment step to enrich for CD4posCD25high Treg 
(referred to as CliniMACS8/25). For comparison, a laboratory 
scale MiniMACS based Treg isolation protocol was also 
performed (referred to as MiniMACS).
Leukapheresis products contained on average 3% 
CD4posCD25high regulatory T  cells (Figure 1 and Table 1). Less 
than 0.1% C D 8pos cells were present in the isolated CliniMACS8/ 
25 populations. While 80% of CliniMACS8/25 cells was
CD4posCD25pos, only 40-60%  was CD4posCD25high (Figure 1A 
and Table 1). MiniMACS based Treg isolation from the same 
leukapheresis product yielded a higher Treg purity with 90% 
CD4posCD25high cells. CliniMACS8/25 populations expressed
lower levels of FoxP3 as compared to MiniMACS isolated Treg 
populations (Figure 1A).
A hallmark of CD4posCD25high Treg is their anergic phenotype, 
defined as low proliferative capacity upon T  cell receptor 
stimulation alone as compared to Tconv cells, which can be 
restored by the addition of exogenous IL-2. Both CliniMACS8/25 
and MiniMACS populations were anergic (Figure 1B).
Suppressive capacity of Treg populations was determined by 
titration of Treg into co-cultures of autologous CD4posCD25neg 
responder T  cells stimulated with allogeneic stimulator PBMC. As 
shown in Figure 1C, Treg populations isolated with the 
CliniMACS8/25 strategy were moderately suppressive, reaching 
50% suppression at a 1:1 Tresp:Treg ratio, while MiniMACS 
isolated Treg populations were more potent, with 50% suppression 
at Tresp:Treg ratios of approximately 4:1.
Expansion of CliniMACS Treg with either polyclonal or 
alloantigen stimulation increases cell numbers while 
suppressive activity is retained
CliniMACS Treg isolation strategies yield high numbers of 
Treg, but these numbers might still be too low for therapeutic 
purposes. This issue can be overcome by ex vivo expansion of Treg. 
To analyze expansion potential and effects of expansion on 
phenotypic and functional characteristics, CliniMACS8/25 isolated 
Treg populations were activated using either polyclonal stimula­
tion (anti-CD3+anti-CD28 mAb coated microbeads) or alloanti­
gen stimulation (irradiated PBMC from an HLA-mismatched 
donor), in the presence of exogenous IL-2.
Polyclonal and alloantigen stimulated expansion cultures 
yielded similar cell numbers (Table 2). CliniMACS8/25 popula­
tions increased about 30-fold in cell numbers in ten days. The 
phenotype of expanded CliniMACS8/25 populations is depicted in
Figure 2A. CD25 expression was high in both CliniMACS8/25 and 
MiniMACS populations, while the expression of FoxP3 was lower 
in expanded CliniMACS8/25 cells as compared to expanded 
MiniMACS populations. After expansion, all Treg populations 
remained anergic (Figure 2B). CliniMACS8/25 and MiniMACS 
populations suppressed alloantigen driven responder T  cell 
proliferation to a similar extent (Figure 2C). Notably, alloantigen 
expanded Treg populations showed higher suppressive capacity in 
alloantigen driven responder T  cell responses as compared to 
polyclonally expanded Treg (>75% suppression at a Tresp:Treg 
ratio of 16:1 versus 50% suppression at Tresp:Treg ratios a 
Tresp:Treg ratio of 8:1, respectively, Figure 2C). This indicates 
that the alloantigen expanded cell populations were enriched for 
alloantigen-specific Treg. As our group has shown previously, the 
low proliferation observed after addition of alloantigen expanded 
Tconv can be explained by distinct culture kinetics with an earlier 
proliferation peak and a net result of lower counts at day 5 [21].
It would be convenient for Treg immunotherapy to be able to 
store Treg cells prior to manipulation an d /o r infusion. The 
suppressive capacity of cryopreserved CliniMACS Treg was 
impaired (Figure 3), and could not be regained by cell resting 
for up to seven days in culture medium. However, expansion of 
cryopreserved CliniMACS cells restored suppressive capacity.
Depletion of CD19pos cells during CliniMACS Treg 
isolation is necessary to prevent B cell contamination
After CliniMACS8/25 isolation procedures, less than 3% B cells 
were present in isolated populations, these numbers increased after 
expansion to 5 to 10% (Figure 4A). In order to remove B cells from 
our CliniMACS isolated Treg populations, we tested the efficacy 
of CD19pos B cell depletion in the CliniMACS isolation procedure.
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Figure 1. Phenotypic and functional characteristics of freshly CliniMACS isolated Treg. Treg were isolated from leukapheresis products in 
GMP CliniMACS-based or non-GMP MiniMACS-based isolation procedures. Data from a typical isolation are shown (N = 3). (A) Cell surface expression 
of CD4 and CD25 and intracellular expression of FoxP3. (B) Proliferative capacity upon stimulation with allogeneic PBMC in the absence or presence of 
exogenous IL-2, measured at day 5 o f culture. (C) Suppressive capacity in co-cultures of autologous naïve CD4posCD25neg Tresp stimulated with 
allogeneic PBMC. Significant differences are indicated by asterisks. In figure C, open and filled asterisks refer to  Tconv (used as control for the addition 
of cells) versus MiniMACS or CliniMACS8/25, respectively. 
doi:10.1371/journal.pone.0003161.g001
In this strategy, first C D 8pos and CD19pos cells were depleted, 
followed by enrichment of CD25pos cells (referred to as 
CliniMACS8/19/25). Less than 0.5% B cells were present after 
these isolations (see Table 1 and Figure 4B) and no substantial B 
cell contaminations arose after either polyclonal or alloantigen 
expansion (see Table 2 and Figure 4B). CliniMACS8/19/25 
populations were similar to CliniMACS8/25 cells with respect to 
the phenotype, anergic state and suppressive potential, both 
directly after isolation as well as after expansion (data not shown). 
Thus, CD19pos depletion effectively prevents B cell contamina­
tions in CliniMACS Treg populations after isolation and after 
expansion.
Depletion of CD127pos cells improves CliniMACS Treg 
purity
CD4posCD25neg/lowFoxP3neg/low Tconv cells were the major
contaminating cell type in CliniMACS isolated Treg (40-60% of 
the isolated populations, see Figure 1). Recently, it has been 
described that Tconv express the IL-7 receptor alpha-chain 
CD127, while Treg cells do not express CD127 [22,23]. Indeed,
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Table 1. Enrichment of CD4posCD25high Treg by CliniMACS isolation.
Num ber o f W B C x10 8 (SD) Percentage o f cells w ith  indicated phenotype (SD)
CD4pos CD4pos CD4pos CD8pos CD20pos
CD25high CD25pos T cell T cell B cell
Leukapheresis* 27.2 (1.9) 3 (3) 8 (8) 60 (1) 26 (7) 16 (15)
CliniMACS8/25 1.5 (0.0) 45 (19) 78 (0) 95 (1) 0 (0) 2 (1)
CliniMACS8/19/25 1.3 (0.1) 46 (13) 81 (5) 97 (1) 0 (0) 0 (0)
MiniMACS - 88 (2) 90 (1) 98 (0) 1 (1) 1 (1)
N = 3.
*Partial leukapheresis products were used.
doi:10.1371/journal.pone.0003161.t001
CliniMACS isolated populations contained both CD127neg and 
CD127pos cells, reflecting the presence of both Treg and Tconv 
cells (Figure 5A). To improve the purity of Treg isolated with 
CliniMACS, we hypothesized that depletion of CD127pos cells 
could be employed to exclude contaminating T  cells. Because anti- 
CD127 CliniMACS beads are currently not available, we depleted 
CD127pos cells from CliniMACS isolated cell populations by 
FACS.
As shown in Figure 5A, this procedure indeed enabled 
separation of Treg from Tconv cells. In contrast to CD127pos 
cells, the majority of CliniMACS CD127neg cells showed a Treg 
phenotype: CD4posCD25high and FoxP3pos. Since we used 
cryopreserved CliniMACS populations for these experiments, we 
expanded the populations prior to functional characterization. 
After expansion, CD127neg populations retained a high Treg 
purity, as evidenced by high expression of CD25 and FoxP3 
(Figure 5B). In contrast to CD127pos populations, CD127neg 
populations were anergic after expansion (Figure 5C). As expected, 
CD127 depletion enhanced suppressive potential, as shown by the 
significantly higher suppressive capacity of CD127neg populations 
as compared to CliniMACS populations that were not depleted of 
CD127pos cells (Figure 5D).
Discussion
Im munotherapy using ex vivo activated an d /o r expanded 
CD4posCD25high regulatory T  cells appears promising, not only 
in stem cell transplantation, but also for a number of autoimmune 
disorders. To be optimally effective, the availability of tailor-made 
clinical grade procedures is a prerequisite. As previously reported 
[14,15], CliniMACS GM P Treg isolation strategies based on 
CD25pos enrichment typically result in 40-60%  pure Treg with 
moderate suppressive activity.
Table 2. Increase in CliniMACS Treg numbers by expansion.
Polyclonal Alloantigen
CliniMACS8/25 31 (16) 28 (14)
CliniMACS8/19/25 34 (17) 34 (11)
MiniMACS 4 (0) 9 (3)
Tconv 46 (1) 55 (10)
Fold increase in cell numbers (SD) after 10 days expansion w ith indicated
stimulus in the presence o f exogenous IL-2, N = 3.
doi:10.1371/journal.pone.0003161.t002
The degree of purity of Treg that is required may depend on the 
actual application. In stem cell transplantation, the first clinical 
trials on Treg immunotherapy have recently been initiated. In 
these studies, either CliniMACS isolated CD4posCD25high Treg 
(with 40-60%  purity) or ex vivo manipulated CD4pos T  cell lines 
consisting of 5-10%  induced regulatory Tr1 cells and conse­
quently a substantial amount of non-Treg were infused in patients 
receiving stem cell transplantations [24]. So far, to our knowledge, 
no adverse effects have been reported. However, caution is 
necessary when applying Treg for auto-immune disease or solid 
organ transplant purposes. Here an inadvertently present effector 
pool might cause serious pathology.
As cytotoxic C D 8pos T  cells are a potentially aggressive cell type 
in immune responses, it is highly recommendable to exclude these 
cells from CliniMACS isolated Treg populations. Here, we show 
that the C D 8pos CliniMACS cell depletion step was effective: less 
than 0.1% C D 8pos cells were present in isolated Treg populations, 
and no outgrowth of C D 8pos cells occurred after expansion of 
CliniMACS Treg populations. Treg isolated by CD25pos enrich­
ment following C D 8pos depletion contained a small contamination 
of B cells (1-3%), which could increase to up to 10% after T  cell 
expansion. The risks of infusion of expanded and activated 
autologous B cells are unknown, but could in theory include the 
development of a B cell lymphoproliferative disorder that can 
occur after transplantation and is often lethal [25-27]. We were 
able to prevent the contamination by B cells by including a 
CD19pos B cell depletion step in the isolation strategy.
Notwithstanding the favorable effects of combined anti-CD25, 
anti-CD8 and anti-CD19 microbead isolation (the currently 
available clinical grade tools), the isolated Treg population was 
of suboptimal purity. Most of the contaminating cells appeared to 
be CD4posCD25neg/low Tconv cells that could potentially lead to 
immunopathology. To further improve CliniMACS Treg purity, 
Wichlan et al. studied titration of anti-CD25 microbeads in the 
enrichment phase of CliniMACS Treg isolation. While the use of 
lower amounts of beads indeed led to populations with higher 
CD25 expression levels [15], the suppressive capacity of the 
isolated populations did not improve and cell yields were 
significantly lower, indicating that titration of CD25 microbeads 
will not provide the solution to achieve higher purity for 
CliniMACS Treg isolation. These authors also reported that 
adjustment of CliniMACS flow rates did not lead to a higher Treg 
purity. Hoffmann et al. used three consecutive CliniMACS 
selection cycles for CD25pos cells, to preferentially select CD25high 
Treg and exclude CD25neg/low Tconv [14]. However, the degree 
of Treg purity obtained with this approach was similar to that 
achieved with one CD25 enrichment cycle.
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Figure 2. Phenotypic and functional characteristics of expanded CliniM ACS isolated Treg. Cell populations were expanded with 
polyclonal stimulus or alloantigen stimulus in the presence of exogenous IL-2. Data from a typical experiment are shown (N = 3). (A) Cell surface 
expression of CD25 and intracellular expression of FoxP3. (B) Proliferative capacity upon restimulation with allogeneic PBMC (same donor as in
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alloantigen expansion) in the absence or presence of exogenous IL-2, measured at day 3 of culture. (C) Suppressive capacity in co-cultures of 
autologous naïve CD4posCD25neg Tresp stimulated with allogeneic PBMC (same donor as in alloantigen expansion). Significant differences are 
indicated by asterisks. In figure C, open and filled asterisks refer to Tconv (expanded with same stimulus as Treg populations) versus MiniMACS or 
CliniMACS8725, respectively. 
doi:10.1371/journal.pone.0003161.g002
Recently, it has been described that Tconv express the IL-7 
receptor alpha chain CD127, while Treg do not express this 
molecule [22,23]. Thus, in the current study, we hypothesized that 
the conventional T  cells contaminating G M P Treg populations 
could be excluded from the CliniMACS isolated populations by 
depleting CD127pos cells. Since anti-CD127-microbeads for use in 
CliniMACS are currently not available, we depleted CD127pos 
cells from CliniMACS isolated Treg populations by FACS. This 
procedure indeed increased Treg purity, as shown by uniformly 
high expression of FoxP3 in CD127neg populations. After 
expansion of CliniMACS CD127neg populations, high expression 
of FoxP3pos was maintained, and the cell populations showed 
potent suppressive capacity. Notably, suppressive capacity of 
CliniMACS CD127neg populations was significantly higher than 
that of non-depleted CliniMACS populations, indicating that 
CD127 depletion clearly enriched for functional Treg.
The outcome of a particular T  cell based immune response is 
likely to be determined by the balance between the effector and 
regulatory T  cell pools. Consequently, the efficacy of Treg therapy 
may be determined by the actual number of antigen reactive Treg 
within the infused cell population. Indeed, antigen-specific Treg 
were proven to be more efficient than polyclonal Treg in 
preclinical mouse models of autoimmunity [6,12,13] and graft-
Figure 3. Cryopreservation of CliniM ACS Treg affects suppres­
sive capacity, which can be restored by activation. Suppressive 
capacity o f cryopreserved CliniMACS Treg in co-cultures of autologous 
naïve CD4posCD25neg Tresp stimulated with allogeneic PBMC. Data from 
a typical experiment are shown (N = 2-4). Prior to  co-culture 
suppression assay, indicated cell populations were expanded for 10 
days in the presence of exogenous IL-2 and allogeneic PBMC (same 
donor as in co-culture suppression assay). Significant differences are 
indicated by asterisks. Open and filled asterisks refer to cryopreserva- 
tion versus cryopreservation plus 4 days rest or cryopreservation plus 
expansion, respectively. 
doi:10.1371/journal.pone.0003161.g003
versus-host disease [3,5,7]. Previously, we and others have shown 
that hum an Treg isolated by non-clinical grade strategies can be 
expanded using both polyclonal and alloantigen stimulation 
methods [16-21]. Importantly, we show in this report that this 
also holds true for clinical grade isolated Treg. Due to the 
moderate purity of CliniMACS isolated Treg populations, 
outgrowth of contaminating cells could be a risk upon expansion. 
Indeed, expanded CliniMACS8/19/25 Treg populations contained 
a significant percentage of FoxP3neg cells, however, this could be 
prevented by depletion of CD127pos cells from the CliniMACS 
isolated Treg populations.
Clinical implementation of Treg based therapy will be highly 
facilitated if Treg can be stored prior to infusion, as this will allow 
a more flexible timing of Treg therapy an d /o r therapeutic 
schemes with multiple Treg treatments over time. We studied 
the feasibility of CliniMACS Treg cryopreservation in liquid 
nitrogen. Results indicate that Treg can survive cryopreservation, 
as thawed populations showed 70-80% cell viability. We noted 
decreased suppressive activity of thawed Treg populations, which 
could be restored by Treg expansion. An alternative approach 
would be to expand Treg prior to cryopreservation. This resulted 
in unaltered suppressive capacity upon thawing, at least in 
MiniMACS isolated Treg (Supplemental data, Figure S1).
In summary, we here provide further support for clinical 
implementation of Treg immunotherapy by showing that a high 
Treg purity can be reached, and that isolated cells can be 
cryopreserved and expanded successfully.
M a te ria ls  an d  M e th o d s
Human cells
Healthy donors were scheduled for leukapheresis procedures to 
obtain leukocytes for donor lymphocyte infusions in hematopoietic 
stem cell transplantation patients in the Radboud University 
Nijmegen Medical Centre. Excess leukapheresis material was used 
for the current study upon written informed consent with regard to 
scientific use. Buffy coats from healthy human donors were 
purchased from Sanquin bloodbank, Nijmegen, The Netherlands, 
upon written informed consent with regard to scientific use and 
used as a source of stimulator PBMC. The current study did not 
require approval from an ethics committee according to the Dutch 
Medical Research Involving H um an Subjects Act.
Treg isolation
Healthy donor leukapheresis products were used for Clin­
iMACS CD4posCD25high Treg isolation. Cells were washed with 
PBS/ED TA  buffer (Miltenyi Biotec, Bergisch-Gladbach, Ger­
many, supplemented with 0.5% HSA (Sanquin bloodbank). Anti- 
C D 8 an d /o r anti-CD19 coated CliniMACS microbeads (kindly 
provided by Miltenyi Biotec) were added, incubated for 30 min­
utes and washed. CliniMACS program 2.1 was run to deplete 
labeled cells (CliniMACS separation columns were kindly 
provided by Miltenyi Biotec). The labeling procedure was 
repeated with anti-CD25 CliniMACS microbeads, and Clini­
MACS program 1.1 was run to enrich for CD25pos cells.
A non-GM P MiniMACS based CD4posCD25high Treg isolation 
method was performed on leukocytes from the same leukapheresis 
products as used for CliniMACS Treg isolation. PBMC were
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Figure 4. B cell contamination can be prevented by depleting C D 19pos cells during CliniM ACS Treg isolation. Percentage of 
contaminating B cells in freshly isolated or alloantigen expanded CliniMACS populations. Data from a typical experiment are shown (N = 3). (A) 
CliniMACS8/25 populations. (B) CliniMACS8/19/25 populations. 
doi:10.1371/journal.pone.0003161.g004
isolated by density gradient centrifugation (Lymphoprep, Ny- 
comed Pharma, Roskilde, Denmark). CD4pos T  cells were 
negatively selected using mAbs directed against C D 8 (RPA-T8), 
CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33 (P67.6), CD235a 
(GA-R2(HIR2) (BD Biosciences, San Jose, CA, USA), and CD56 
(MOC-1) (Dako, Glostrup, Denmark) combined with sheep-anti- 
mouse-IgG coated magnetic beads (Dynal Biotech, Oslo, Norway), 
routinely resulting in a >90%  pure CD4pos T  cell fraction. 
CD25high Treg and CD25neg conventional T  cells (referred to as 
Tconv, included in all experiments as control cell population) were 
separated by MACS-sorting, using 10 ml anti-CD25 magnetic 
microbeads/107 CD4pos cells (Miltenyi Biotec).
For CD127pos cell depletion, CliniMACS isolated Treg were 
stained with anti-CD127-AlexaFluor647 (BD Biosciences) and 
CD127pos cells were depleted on an Elite FACS machine 
(Beckman Coulter, Fullerton, CA, USA).
Stimulator PBMC were isolated from healthy donor buffy coat 
by density gradient centrifugation (Lymphoprep, Nycomed 
Pharma).
HLA typing was performed by serological and DNA based 
techniques according to international (ASHI/EFI) standards [28].
Treg cryopreservation
Treg cells were suspended in RPM I 1640 supplemented with 
pyruvate (0,02 mM), penicillin (100 U/ml), streptomycin (100 m g/ 
ml), 20% human pooled serum (HPS) and 15% dimethylsulfoxide, 
were kept in — 80°C for one week, and were subsequently 
transferred to liquid nitrogen for up to one year. Cells were quickly 
thawed in a 37°C water bath and washed twice before use.
Treg expansion
Cell cultures were performed in culture medium consisting of 
RPM I 1640 supplemented with pyruvate (0.02 mM), penicillin 
(100 U/m l), streptomycin (100 mg/ml), 10% HPS and IL-2 
(25 U /m l, Chiron, Amsterdam, the Netherlands) with 5x104 cells 
per well in 96-well round bottom plates, in a 37°C, 95% humidity, 
5% C O 2 incubator. Stimulation was provided by either 105 
irradiated (30 Gy) fully HLA-mismatched allogeneic PBMC per
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Figure 5. CliniM ACS Treg isolation can be improved by depleting CD 127pos Tconv cells. CliniMACS populations were stained with anti- 
CD127 and sorted into CD127neg and CD127pos subsets. CliniMACS cells were cryopreserved prior to cell sorting. Data from one o f two similar 
experiments are shown. (A) Cell surface expression o f CD127, CD4 and CD25 and intracellular expression o f FoxP3. (B-C-D) CliniMACS populations 
were expanded with alloantigen stimulation and exogenous IL-2. (B) Cell surface expression of CD25 and intracellular expression o f FoxP3. (C)
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Proliferative capacity upon restimulation with allogeneic PBMC (same donor as in alloantigen expansion) in the absence or presence o f exogenous IL-
2. (D) Suppressive capacity in co-cultures o f autologous naïve CD4posCD25neg Tresp stimulated with allogeneic PBMC (same donor as in alloantigen 
expansion). Significant differences are indicated by asterisks. In figure D, open and filled asterisks refer to CliniMACS versus CliniMACS CD127pos or 
CliniMACS CD127neg, respectively. 
doi:10.1371/journal.pone.0003161.g005
well (alloantigen expansion) or 1 x104 anti-CD3+anti-CD28 mAb 
coated microbeads per well (Dynal Biotech, polyclonal expansion).
Wells were split and provided with fresh medium containing 
cytokines every 3 days. After 10 days, the cells were harvested, 
washed and rested for 2 days in 5% HPS culture medium before 
functional and phenotypic analyses.
Flow cytometry
The phenotype of cells was analyzed by five-color flow 
cytometry (FC500, Beckman Coulter). For cell surface staining, 
the following conjugated mAbs were used: anti- 
CD4(SFCI12T4D11)-PCy7, anti-CD19(J4.119)-PE (Beckman 
Coulter), anti-CD25(4E3)-biotin, anti-biotin(Bio3-18E7)-PE (used 
in Figures 1 and 2), anti-CD20(LT20)-PE (Miltenyi Biotec), anti- 
CD25(M-A251)-PE (used in Figure 5), and anti-CD127(hIL-7R- 
M21)-AlexaFluor647 (BD Biosciences). For intracellular staining, 
Fix and Fix/Perm  buffer and anti-FoxP3(PCH101)-FITC were 
used according to the manufacturer’s instructions (eBioscience, 
San Diego, CA, USA). Isotype controls were used for gate settings.
Stimulation assay to analyze T cell anergy
T  cell anergy was examined in (re-)stimulation assays. 
2 .5x104 cells were stimulated with 105 irradiated allogeneic 
stimulator PBMC in the presence or absence of IL-2 (12.5 U / 
ml). Proliferation was measured at day 5 (primary responses) or 
day 3 (secondary responses). To this end, 0.5 mCi [3H]Thymidine 
(Amersham Biosciences, Piscataway, NJ) was added to each well. 
After 8 hours, [3H]Thymidine incorporation was measured using 
a beta-plate counter (Packard, Canberra, Australia). Tests were set 
up in triplicate; results were expressed as mean+SD counts per 
5 minutes.
Co-culture suppression assays
Suppressive capacity of Treg was studied in co-culture 
suppression assays. 5x104 autologous responder T  cells 
(CD4posCD25neg, Tresp) were stimulated with 105 irradiated
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